Floatz logo

Cald Hr-D

Mucopolysaccharidosis

Masonic Cancer Center, University of MinnesotaunclassifiedPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Mucopolysaccharidosis cohort.

Asset / SponsorPhaseRating
.Beta.-Glucuronidase (Synthetic Human), Homotetramer
Ultragenyx Pharmaceutical Inc
Phase 3BBB
Rituximab
Takeda
Phase 4BB
Idursulfase
Takeda
Phase 4BB
Methotrexate
Takeda
Phase 4BB
Human Immunoglobulins
Takeda
Phase 4B

View all 13 →

Same molecule, other indications

Cald Hr-D is also rated in:

peroxisome biogenesis disorder type 3BActive
CCC
Indicative · Phase 2
53 / 100
View asset →
Hurler syndromeActive
CCC
Indicative · Phase 2
53 / 100
View asset →
peroxisome biogenesis disorderActive
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →